Drug Price Trends for BRIVIACT

Average Pharmacy Cost for BRIVIACT

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
BRIVIACT 100 MG TABLET	50474-0770-66	23.50947	EACH	2025-01-01
BRIVIACT 100 MG TABLET	50474-0770-09	23.50947	EACH	2025-01-01
BRIVIACT 75 MG TABLET	50474-0670-66	23.53587	EACH	2025-01-01
BRIVIACT 10 MG TABLET	50474-0370-66	23.50675	EACH	2025-01-01

Market Analysis and Price Projections for Briviact (Brivaracetam)

Introduction to Briviact

Briviact, or brivaracetam, is a pyrrolidine anticonvulsant developed by UCB, primarily used for the treatment of epilepsy, particularly partial onset seizures. It is part of the ‘racetam’ class of medicines, known for its high, selective affinity for synaptic vesicle protein 2A (SV2A), which is crucial for its anticonvulsant effect[1].

Market Approval and Expansion

Briviact was initially approved as an adjunctive therapy for partial onset seizures in epilepsy patients aged 16 years and older in January 2016. Later, in September 2017, it received approval as a monotherapy for the same condition, significantly expanding its potential patient population[1].

UCB is actively working to further expand Briviact's market penetration. This includes potential approval for pediatric patients, which could extend the drug's exclusivity period by six months, delaying generic entry. Additionally, UCB plans to launch Briviact in Japan as both a monotherapy and adjunctive therapy for epilepsy patients with partial onset seizures[1].

Market Projections

GlobalData forecasts that Briviact will launch in all seven major markets (7MM) and is expected to reach peak sales of $353 million by 2025, making it one of the highest-selling anti-epileptic drugs (AEDs) on the market[1].

Pricing and Affordability

The pricing of Briviact varies based on the form and dosage of the medication. Here are some key pricing points:

• Oral Tablets: The cost for Briviact oral tablets can range from approximately $1,522.70 for a supply of 60 tablets, regardless of the dosage (10 mg, 25 mg, 50 mg, 75 mg, or 100 mg)[2].
• Intravenous Solution: The intravenous solution costs around $658.03 for 50 milliliters[2].
• Oral Liquid: The oral liquid form costs about $1,522.71 for 300 milliliters[2].

Patient Affordability

Despite the high list price, many patients find Briviact affordable due to insurance and discount programs. About 86% of Briviact prescriptions cost patients between $0 and $100 per month, with the remaining 14% typically costing $100 per month. The list price of Briviact is $1,437.04 per month, but actual costs vary widely depending on the patient's insurance plan[5].

Budget Impact Analysis

Studies have been conducted to analyze the budget impact of introducing Briviact into the treatment portfolio for epilepsy. These analyses, particularly in the Spanish National Health System, indicate that Briviact can lead to significant savings.

• Target Population: The target population eligible for adjunctive antiepileptics is estimated to be around 2,352 patients between 2016 and 2020[3][4].
• Annual Expenditure: Annual expenditure on antiepileptics is approximately €3.6 million. The introduction of Briviact is projected to create annual savings of 0.09-0.37%, representing €41,873 over five years[3][4].
• Sensitivity Analysis: The sensitivity analysis suggests that the probability of achieving savings with Briviact is around 84%, indicating robust savings potential for the health system[3][4].

Market Share and Competition

Briviact's market share is expected to grow as it displaces other existing AEDs. The budget impact analysis models simulate Briviact entering the market and drawing a market share from other available therapies. The most used AEDs are expected to be the most displaced, leading to an increasingly large budget saving over time[3].

Future Outlook

Given its favorable budget impact and expanding approvals, Briviact is poised to become a significant player in the epilepsy treatment market. UCB's strategies to expand its market penetration, including potential pediatric approvals and launches in new markets, are likely to further solidify Briviact's position.

Key Takeaways

• Approval and Expansion: Briviact has been approved as both a monotherapy and adjunctive therapy for partial onset seizures and is expected to expand into pediatric and Japanese markets.
• Market Projections: Peak sales are forecasted to reach $353 million by 2025.
• Pricing: High list prices, but patient costs are often between $0 and $100 per month due to insurance and discount programs.
• Budget Impact: Introduction of Briviact is expected to create significant savings for health systems, with an 84% probability of achieving savings.
• Market Share: Briviact is expected to displace other AEDs, leading to increased market share and budget savings.

FAQs

Q: What is Briviact used for? A: Briviact (brivaracetam) is used for the treatment of partial onset seizures in epilepsy patients aged 16 years and older.

Q: How much does Briviact cost? A: The list price of Briviact is around $1,437.04 per month, but patient costs can range from $0 to $100 per month due to insurance and discount programs.

Q: Is Briviact available as a generic? A: No, Briviact is currently available only as a brand name drug; a generic version is not yet available[2].

Q: What are the projected sales of Briviact by 2025? A: Briviact is forecasted to reach peak sales of $353 million by 2025[1].

Q: How does Briviact impact the health system budget? A: Studies indicate that the introduction of Briviact can lead to annual savings of 0.09-0.37% in antiepileptic expenditures, representing significant savings for health systems[3][4].

Sources

1. UCB's latest anti-epileptic drug advances in the epilepsy market - Clinical Trials Arena
2. Briviact Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
3. Budget Impact Analysis of Brivaracetam Adjunctive Therapy - RiuNet
4. Budget Impact Analysis of Brivaracetam Adjunctive Therapy for ... - PubMed
5. How much should I expect to pay for Briviact® (brivaracetam) CV? - UCB USA